StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
OVIDOvid Therapeutics Inc.
stockpulse.co.kr
Nasdaq
$2.20▲ 2.56%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $410.6MShares out 1.900M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

5
  • 8.24After-hours26.08.25 05:47
    144Ownership#●●●#●●●#●●●

    Ovid Therapeutics Inc.Bullish

    Ovid Therapeutics Inc. insider Jeffrey A. Rona has filed an SEC Form 144 to report a proposed sale of company shares. This filing formalizes the insider's plan to dispose of their holdings, which may result in equity dilution and downward pressure on the stock price for shareholders.…more

    $2.20+2.56%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 8.17Pre-market26.08.15 07:27filed
    144Ownership

    Ovid Therapeutics Inc.

    Jeffrey A. Rona of Ovid Therapeutics Inc. filed an SEC Form 144 on August 14, 2026, to report a proposed sale of company securities. This filing formalizes the insider's intent to dispose of shares, which will result in the supply of these shares to the market.…more

    $2.20+2.56%vs prev close
    View filingShare
  • 8.13Pre-market26.08.13 21:33
    10-QEarnings

    Ovid Therapeutics Inc.

    Ovid Therapeutics filed its quarterly report (10-Q) for the period ending June 30, 2026. Additionally, the company entered into a consulting agreement with Karen Bernstein effective June 10, 2026, granting a total fee of $45,000 and an option to purchase 50,000 shares of common stock over a one-year term.…more

    $2.20+2.56%vs prev close
    View filingShare

4 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.3Pre-market26.09.03 21:00
    #●●●#●●●

    Ovid Therapeutics to Participate in Upcoming Investor Conferences

    Ovid Therapeutics announced that its management will participate in two upcoming global healthcare investor conferences in September. The company will present its business updates and pipeline progress during these sessions.…more

    $2.20+2.56%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 8.13Pre-market26.08.13 21:30

    ●●●●●●●● ●●●●● ●●●●●●

    Ovid Therapeutics provided updates on its clinical pipeline, including OV4071 and OV329, while confirming a financial runway extending into 2029. The company also expects future milestone payments and royalties following the strategic divestiture of its soticlestat interests.…more

    $2.20+2.56%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →